novo nordisk weight loss

News

Novo Nordisk, Wegovy obesity drug

Novo Nordisk's Wegovy weight loss drug sales soar 67% in second quarter

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from compounded drug makers. The pharma giant last week cut its full-year guidance and named Mike Doustdar as its new CEO.

Reuters on MSN · 20h

Novo Nordisk's weight loss challenge in five charts

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market capitalization since mid last year as competition from U.S. rival Eli Lilly and Co (LLY.N) and copycat rivals has hardened.

Yahoo Finance · 10h

Novo Nordisk warns copycat drugs continue weighing on sales

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales and lawmakers push for lower prices. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani outlines the latest and shares what she learned from her interview with Novo Nordisk CFO Karsten Munk Knudsen.

BioPharma Dive8h

Novo pushes back against obesity drug compounders as competition intensifies

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

1don MSN

Why Novo Nordisk Stock Is Down Again Today

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

6don MSN

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

Danish leader will face a challenging landscape among competitors ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results